|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
JP2003521448A
(ja)
*
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6872739B1
(en)
*
|
1999-06-04 |
2005-03-29 |
Vereniging Voor Christelijk Wetenshappelikjk Onderwijs |
Use of riluzole for the treatment of multiple sclerosis
|
|
EP1187612B1
(en)
*
|
1999-06-04 |
2005-01-26 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Use of riluzole for the treatment of multiple sclerosis
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
WO2001060392A1
(en)
*
|
2000-02-18 |
2001-08-23 |
Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science |
Oral, nasal and pulmonary dosage formualtions of copolymer 1
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
CA2411536A1
(en)
*
|
2000-06-05 |
2001-12-13 |
V. Wee Yong |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
SI1459065T1
(sl)
|
2001-12-04 |
2010-11-30 |
Teva Pharma |
Postopki za merjenje potentnosti glatiramer acetata
|
|
PL215263B1
(pl)
|
2002-02-25 |
2013-11-29 |
Elan Pharm Inc |
Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
|
|
CA2514125A1
(en)
*
|
2003-01-24 |
2004-08-12 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
|
WO2006029411A2
(en)
|
2004-09-09 |
2006-03-16 |
Yeda Research And Development Co. Ltd. |
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
|
|
ES2612001T4
(es)
|
2009-08-20 |
2018-02-07 |
Yeda Research & Development Company, Ltd. |
Terapia de baja frecuencia con acetato de glatirámero
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
NZ703122A
(en)
|
2010-10-11 |
2016-06-24 |
Teva Pharma |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
KR20140101730A
(ko)
|
2011-10-10 |
2014-08-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
|
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
CN105884866B
(zh)
*
|
2015-01-26 |
2021-04-20 |
漳州未名博欣生物医药有限公司 |
格拉替雷的化学合成方法
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
CN112649537B
(zh)
*
|
2015-04-28 |
2024-03-29 |
深圳翰宇药业股份有限公司 |
多肽混合物高效液相色谱分析方法
|
|
US12097292B2
(en)
|
2016-08-28 |
2024-09-24 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
HUE071047T2
(hu)
|
2016-08-31 |
2025-07-28 |
Mapi Pharma Ltd |
Glatiramer-acetátot tartalmazó depórendszerek
|
|
CN110382052A
(zh)
|
2017-03-26 |
2019-10-25 |
Mapi医药公司 |
用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
|
|
JP2020525459A
(ja)
|
2017-06-26 |
2020-08-27 |
アンスティテュ・パストゥール |
Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
|